The safety of treatment options for acute bacterial skin and skin structure infections

References

• Livermore DM, Mushtaq S, Warner M, et al. Pathogens of skin and skin-structure infections in the UK and their susceptibility to antibiotics, including ceftaroline. J Antimicrob Chemother. 2015 Oct;70(10):2844–2853.
   PubMed Web of Science ®Google Scholar
• Russo A, Concia E, Cristini F, et al. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections. Clin Microbiol Infect. 2016 Apr;22(Suppl 2):S27–36.
   PubMed Web of Science ®Google Scholar
• Esposito S, Noviello S, Leone S. Epidemiology and microbiology of skin and soft tissue infections. Curr Opin Infect Dis. 2016 Apr;29(2):109–115.
   PubMed Web of Science ®Google Scholar
• Edelsberg J, Berger A, Weber DJ, et al. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol. 2008 Feb;29(2):160–169.
   PubMed Web of Science ®Google Scholar
• Garau J, Ostermann H, Medina J, et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect. 2013 Sep;19(9):E377–85.
   PubMed Web of Science ®Google Scholar
• Pallin DJ, Egan DJ, Pelletier AJ, et al. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med. 2008 Mar;51(3):291–298.
   PubMed Web of Science ®Google Scholar
• Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010 Sep 15;51(6):641–650.
   PubMed Web of Science ®Google Scholar
• Blumenthal KG, Kuhlen JL Jr., Weil AA, et al. Adverse drug reactions associated with ceftaroline use: A 2-center retrospective cohort. J Allergy Clin Immunol Pract. 2016 Jul Aug;4(4):740–746.
   PubMed Web of Science ®Google Scholar
• Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis. 2002 Aug 15;35(4):381–389.
   PubMed Web of Science ®Google Scholar
• Nicodemo AC, Robledo JA, Jasovich A, et al. A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections. Int J Clin Pract. 1998 Mar;52(2):69–74.
   PubMed Web of Science ®Google Scholar
• Schaper NC, Dryden M, Kujath P, et al. Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study. Infection. 2013 Feb;41(1):175–186.
   PubMed Web of Science ®Google Scholar
• Vick-Fragoso R, Hernandez-Oliva G, Cruz-Alcazar J, et al. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections. Infection. 2009 Oct;37(5):407–417.
   PubMed Web of Science ®Google Scholar
• Miller LG, Daum RS, Creech CB, et al. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. N Engl J Med. 2015 Mar 19;372(12):1093–1103.
   PubMed Web of Science ®Google Scholar
• Brindle R, Williams OM, Davies P, et al. Adjunctive clindamycin for cellulitis: a clinical trial comparing flucloxacillin with or without clindamycin for the treatment of limb cellulitis. BMJ Open. 2017 Mar 17;7(3):e013260.
   PubMed Web of Science ®Google Scholar
• Chen AE, Carroll KC, Diener-West M, et al. Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections. Pediatrics. 2011 Mar;127(3):e573–80.
   PubMed Web of Science ®Google Scholar
• Thwaites GE, Scarborough M, Szubert A, et al. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Feb 17;391(10121):668–678.
   PubMed Web of Science ®Google Scholar
• O’Riordan WAGS, Overcash JS, Puljiz I, et al. A phase 3 randomized, double-blind, multi-center study to compare the safety and efficacy of oral and IV omadacycline to linezolid for treating adult subjects with ABSSSI (the OASIS study). Abstr 630. 27th Eur Congr Clin Microbiol Infect Dis (ECCMID); Vienna, Austria; 22–25 April 2017.
   Google Scholar
• Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother. 2005 Nov;49(11):4658–4666.
   PubMed Web of Science ®Google Scholar
• Lauf L, Ozsvar Z, Mitha I, et al. Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis. Diagn Microbiol Infect Dis. 2014 Apr;78(4):469–480.
   PubMed Web of Science ®Google Scholar
• Aikawa N, Kusachi S, Mikamo H, et al. Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections. J Infect Chemother. 2013 Jun;19(3):447–455.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Efficacy and safety of daptomycin versus vancomycin or teicoplanin for treatment of complicated skin and soft tissue infections.https://clinicaltrials.gov/ct2/show/NCT00430937.
   Google Scholar
• Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005 Jun;49(6):2260–2266.
   PubMed Web of Science ®Google Scholar
• Shorr AF, Lodise TP, Corey GR, et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015 Feb;59(2):864–871.
   PubMed Web of Science ®Google Scholar
• Tanus T, Scangarella-Oman NE, Dalessandro M, et al. A randomized, double-blind, comparative study to assess the safety and efficacy of topical retapamulin ointment 1% versus oral linezolid in the treatment of secondarily infected traumatic lesions and impetigo due to methicillin-resistant Staphylococcus aureus. Adv Skin Wound Care. 2014 Dec;27(12):548–559.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Safety and efficacy of BAY1192631 in Japanese patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. https://clinicaltrials.gov/ct2/show/NCT01967225.
   Google Scholar
• ClinicalTrials.gov. Efficacy and safety of intravenous to oral 6 day tedizolid phosphate vs. intravenous to oral 10 day linezolid in patients with acute bacterial skin and skin structure infection (ABSSSI).https://clinicaltrials.gov/ct2/show/study/NCT02066402.
   Google Scholar
• Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008 Jun 1;46(11):1683–1693.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Evaluation of daptomycin for the emergency department treatment of complicated skin and skin structure infections.https://clinicaltrials.gov/ct2/show/results/NCT01549613.
   Google Scholar
• Huang DB, O’Riordan W, Overcash JS, et al. A phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim vs vancomycin for the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to gram-positive pathogens: REVIVE-1. Clin Infect Dis. 2018 Apr 3;66(8):1222–1229.
   PubMed Web of Science ®Google Scholar
• Kopterides P, Papadomichelakis E, Armaganidis A. Linezolid use associated with lactic acidosis. Scand J Infect Dis. 2005;37(2):153–154.
   PubMed Web of Science ®Google Scholar
• Sawyer AJ, Haley HL, Baty SR, et al. Linezolid-induced lactic acidosis corrected with sustained low-efficiency dialysis: a case report. Am J Kidney Dis. 2014 Sep;64(3):457–459.
   PubMed Web of Science ®Google Scholar
• Wiener M, Guo Y, Patel G, et al. Lactic acidosis after treatment with linezolid. Infection. 2007 Jun;35(4):278–281.
   PubMed Web of Science ®Google Scholar
• Del Pozo JL, Fernandez-Ros N, Saez E, et al. Linezolid-induced lactic acidosis in two liver transplant patients with the mitochondrial DNA A2706G polymorphism. Antimicrob Agents Chemother. 2014 Jul;58(7):4227–4229.
   PubMed Web of Science ®Google Scholar
• IDSA guidelines, Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. Clin Infect Dis. 2004 Jun 15;38(12):1651–1672.
   PubMed Web of Science ®Google Scholar
• Estes J. Mayo clinic- antimicrobial therapy: quick guide vol. laboratory and clinical toxicity monitoring. Mayo Clinic Scientific Press And Informa Healthcare USA, Inc.; 2008.
   Google Scholar
• Har D, Solensky R. Penicillin and beta-lactam hypersensitivity. Immunol Allergy Clin North Am. 2017 Nov;37(4):643–662.
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Tulkens PM. Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother. 2011 Jul;66(7):1431–1446.
   PubMed Web of Science ®Google Scholar
• Dryden M, Zhang Y, Wilson D, et al. A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities. J Antimicrob Chemother. 2016 Dec;71(12):3575–3584.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E. Safety profiles of old and new antimicrobials for the treatment of MRSA infections. Expert Opin Drug Saf. 2016;15(4):467–481.
   PubMed Web of Science ®Google Scholar
• LaVie KW, Anderson SW, O’Neal HR Jr., et al. Neutropenia associated with long-term ceftaroline use. Antimicrob Agents Chemother. 2016 Jan;60(1):264–269.
   PubMed Web of Science ®Google Scholar
• Varada NL, Sakoulas G, Lei LR, et al. Agranulocytosis with ceftaroline high-dose monotherapy or combination therapy with clindamycin. Pharmacotherapy. 2015 Jun;35(6):608–612.
   PubMed Web of Science ®Google Scholar
• Furtek KJ, Kubiak DW, Barra M, et al. High incidence of neutropenia in patients with prolonged ceftaroline exposure. J Antimicrob Chemother. 2016 Jul;71(7):2010–2013.
   PubMed Web of Science ®Google Scholar
• Panagiotidis G, Backstrom T, Asker-Hagelberg C, et al. Effect of ceftaroline on normal human intestinal microflora. Antimicrob Agents Chemother. 2010 May;54(5):1811–1814.
   PubMed Web of Science ®Google Scholar
• Hernandez PO, Lema S, Tyring SK, et al. Ceftaroline in complicated skin and skin-structure infections. Infect Drug Resist. 2012;5:23–35.
   PubMedGoogle Scholar
• Liapikou A, Cilloniz C, Torres A. Ceftobiprole for the treatment of pneumonia: a European perspective. Drug Des Devel Ther. 2015;9:4565–4572.
   PubMedGoogle Scholar
• Murthy B, Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet. 2008;47(1):21–33.
   PubMed Web of Science ®Google Scholar
• Hodille E, Rose W, Diep BA, et al. The role of antibiotics in modulating virulence in Staphylococcus aureus. Clin Microbiol Rev. 2017 Oct;30(4):887–917.
   PubMed Web of Science ®Google Scholar
• Pfizer. Cleocin phosphate injection [prescribing information]. New York, NY; 2018 Aug.
   Google Scholar
• Smieja M. Current indications for the use of clindamycin: A critical review. Can J Infect Dis. 1998 Jan;9(1):22–28.
   PubMedGoogle Scholar
• Geric B, Rupnik M, Gerding DN, et al. Distribution of clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol. 2004 Sep;53(Pt 9):887–894.
   PubMed Web of Science ®Google Scholar
• Andriole VT. The quinolones: past, present, and future. Clin Infect Dis. 2005 Jul 15;41(Suppl 2):S113–9.
   PubMed Web of Science ®Google Scholar
• Owens RC Jr., Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005 Jul 15;41(Suppl 2):S144–57.
   PubMed Web of Science ®Google Scholar
• Mandell L, Tillotson G. Safety of fluoroquinolones: an update. Can J Infect Dis. 2002 Jan;13(1):54–61.
   PubMedGoogle Scholar
• Lee CC, Lee MG, Hsieh R, et al. Oral fluoroquinolone and the risk of aortic dissection. J Am Coll Cardiol. 2018 Sep 18;72(12):1369–1378.
   PubMed Web of Science ®Google Scholar
• Stephenson AL, Wu W, Cortes D, et al. Tendon injury and fluoroquinolone use: a systematic review. Drug Saf. 2013 Sep;36(9):709–721.
   PubMed Web of Science ®Google Scholar
• Administration FaD. FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions. FDA News Release 2018.
   Google Scholar
• Righi E, Carnelutti A, Vena A, et al. Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin. Infect Drug Resist. 2018;11:479–488.
   PubMed Web of Science ®Google Scholar
• Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother. 2011 Feb;55(2):649–658.
   PubMed Web of Science ®Google Scholar
• Jorgensen SCJ, Mercuro NJ, Davis SL, et al. Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties. Infect Dis Ther. 2018 Jun;7(2):197–217.
   PubMed Web of Science ®Google Scholar
• Lodise T, Corey R, Hooper D, et al. Safety of delafloxacin: focus on adverse events of special interest. Open Forum Infect Dis. 2018 Oct;5(10):ofy220.
   PubMed Web of Science ®Google Scholar
• Dawe RS, Ferguson J, Ibbotson S, et al. Lack of phototoxicity potential with delafloxacin in healthy male and female subjects: comparison to lomefloxacin. Photochem Photobiol Sci. 2018 Jun 13;17(6):773–780.
   PubMed Web of Science ®Google Scholar
• Litwin JS, Benedict MS, Thorn MD, et al. A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization. Antimicrob Agents Chemother. 2015;59(6):3469–3473.
   PubMed Web of Science ®Google Scholar
• O’Riordan W, Mehra P, Manos P, et al. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis. 2015;30:67–73.
   PubMed Web of Science ®Google Scholar
• Kingsley J, Mehra P, Lawrence LE, et al. A randomized, double-blind, phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrob Chemother. 2016 Mar;71(3):821–829.
   PubMed Web of Science ®Google Scholar
• Pullman J, Gardovskis J, Farley B, et al. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a phase 3, double-blind, randomized study. J Antimicrob Chemother. 2017 Dec 1;72(12):3471–3480.
   PubMed Web of Science ®Google Scholar
• O’Riordan W, McManus A, Teras J, et al. A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study. Clin Infect Dis. 2018 Aug 16;67(5):657–666.
   PubMed Web of Science ®Google Scholar
• Hoover RK, Alcorn H Jr., Lawrence L, et al. Delafloxacin pharmacokinetics in subjects with varying degrees of renal function. J Clin Pharmacol. 2018 Apr;58(4):514–521.
   PubMed Web of Science ®Google Scholar
• Ocheretyaner ER, Park TE. Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and pseudomonas aeruginosa. Expert Rev Anti Infect Ther. 2018 Jul;16(7):523–530.
   PubMed Web of Science ®Google Scholar
• Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005 Nov 1;41(9):1254–1260.
   PubMed Web of Science ®Google Scholar
• Blaser J, Vergeres P, Widmer AF, et al. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob Agents Chemother. 1995 May;39(5):1134–1139.
   PubMed Web of Science ®Google Scholar
• Zimmerli W, Widmer AF, Blatter M, et al., Foreign-Body Infection (FBI) Study Group. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Jama. 1998 May 20;279(19):1537–1541.
   PubMed Web of Science ®Google Scholar
• Iyer S, Jones DH. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol. 2004 Jun;50(6):854–858.
   PubMed Web of Science ®Google Scholar
• Palmer SM, Rybak MJ. Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots. Antimicrob Agents Chemother. 1996 Mar;40(3):701–705.
   PubMed Web of Science ®Google Scholar
• Craven N, Anderson JC. Therapy of experimental staphylococcal mastitis in the mouse with cloxacillin and rifampicin, alone and in combination. Res Vet Sci. 1981 Nov;31(3):295–300.
   PubMed Web of Science ®Google Scholar
• Schaad HJ, Chuard C, Vaudaux P, et al. Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1994 Aug;38(8):1703–1710.
   PubMed Web of Science ®Google Scholar
• Bouza E. New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2009 Dec;15(Suppl 7):44–52.
   PubMed Web of Science ®Google Scholar
• Muthukumar T, Jayakumar M, Fernando EM, et al. Acute renal failure due to rifampicin: a study of 25 patients. Am J Kidney Dis. 2002 Oct;40(4):690–696.
   PubMed Web of Science ®Google Scholar
• Sakashita K, Murata K, Takahashi Y, et al. A case series of acute kidney injury during anti-tuberculosis treatment. Intern Med. 2019 Feb 15;58(4):521–527.
   PubMed Web of Science ®Google Scholar
• Esposito S, Bassetti M, Concia E, et al. Diagnosis and management of skin and soft-tissue infections (SSTI) . A literature review and consensus statement: an update. J Chemother. 2017 Aug;29(4):197–214.
   PubMed Web of Science ®Google Scholar
• Montravers P, Snauwaert A, Welsch C. Current guidelines and recommendations for the management of skin and soft tissue infections. Curr Opin Infect Dis. 2016 Apr;29(2):131–138.
   PubMed Web of Science ®Google Scholar
• Szumowski JD, Cohen DE, Kanaya F, et al. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother. 2007 Feb;51(2):423–428.
   PubMed Web of Science ®Google Scholar
• Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008 Feb 15;46(4):584–593.
   PubMed Web of Science ®Google Scholar
• Crellin E, Mansfield KE, Leyrat C, et al. Trimethoprim use for urinary tract infection and risk of adverse outcomes in older patients: cohort study. Bmj. 2018 Feb 9;360:k341.
   PubMed Web of Science ®Google Scholar
• Fraser TN, Avellaneda AA, Graviss EA, et al. Acute kidney injury associated with trimethoprim/sulfamethoxazole. J Antimicrob Chemother. 2012 May;67(5):1271–1277.
   PubMed Web of Science ®Google Scholar
• Talan DA, Mower WR, Krishnadasan A, et al. Trimethoprim-sulfamethoxazole versus placebo for uncomplicated skin abscess. N Engl J Med. 2016 Mar 3;374(9):823–832.
   PubMed Web of Science ®Google Scholar
• Ge IY, Fevrier HB, Conell C, et al. Reducing risk of Clostridium difficile infection and overall use of antibiotic in the outpatient treatment of urinary tract infection. Ther Adv Urol. 2018 Oct;10(10):283–293.
   PubMed Web of Science ®Google Scholar
• Brown GR. Cotrimoxazole - optimal dosing in the critically ill. Ann Intensive Care. 2014;4:13.
   PubMed Web of Science ®Google Scholar
• Huang DB, Strader CD, MacDonald JS, et al. An updated review of iclaprim: a potent and rapidly bactericidal antibiotic for the treatment of skin and skin structure infections and nosocomial pneumonia caused by gram-positive including multidrug-resistant bacteria. Open Forum Infect Dis. 2018 Feb;5(2):ofy003.
   PubMed Web of Science ®Google Scholar
• Huang DB, Corey GR, Holland TL, et al. Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections. Int J Antimicrob Agents. 2018 Aug;52(2):233–240.
   PubMed Web of Science ®Google Scholar
• Inc MB. MotifBio receives complete response letter from the FDA. cited 2019 May 10.
   Google Scholar
• plc MB. MotifBio meeting with U.S. FDA held as planned cited 2019 May 10.
   Google Scholar
• Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005 Sep;27(9):1329–1342.
   PubMed Web of Science ®Google Scholar
• Tariq R, Cho J, Kapoor S, et al. Low risk of primary clostridium difficile infection with tetracyclines: a systematic review and metaanalysis. Clin Infect Dis. 2018 Feb 1;66(4):514–522.
   PubMed Web of Science ®Google Scholar
• Villano S, Steenbergen J, Loh E. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiol. 2016 Oct;11:1421–1434.
   PubMed Web of Science ®Google Scholar
• Montravers P, Tran-Dinh A, Tanaka S. The role of omadacycline in skin and soft tissue infections. Curr Opin Infect Dis. 2018 Apr;31(2):148–154.
   PubMed Web of Science ®Google Scholar
• Markham A, Keam SJ. Omadacycline: first global approval. Drugs. 2018 Dec;78(18):1931–1937.
   PubMed Web of Science ®Google Scholar
• Montravers P, Bassetti M, Dupont H, et al. Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother. 2013 Jul;68(Suppl 2):ii15–24.
   PubMed Web of Science ®Google Scholar
• Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005 Sep 1;41(Suppl 5):S341–53.
   PubMed Web of Science ®Google Scholar
• McGovern PC, Wible M, Korth-Bradley JM, et al. Pancreatitis in tigecycline phase 3 and 4 clinical studies. J Antimicrob Chemother. 2014 Mar;69(3):773–778.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, DeMaio W, Jordan RA, et al. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos. 2007 Sep;35(9):1543–1553.
   PubMed Web of Science ®Google Scholar
• Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis. 2000 Jan;30(1):146–151.
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother. 2003 Jun;47(6):1824–1831.
   PubMed Web of Science ®Google Scholar
• Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006 Jan 1;42(1):66–72.
   PubMed Web of Science ®Google Scholar
• Hau T. Efficacy and safety of linezolid in the treatment of skin and soft tissue infections. Eur J Clin Microbiol Infect Dis. 2002 Jul;21(7):491–498.
   PubMed Web of Science ®Google Scholar
• Ferry T, Ponceau B, Simon M, et al. Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases. Infection. 2005 Jun;33(3):151–154.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Patel N, Rivera A, et al. Comparative evaluation of serotonin toxicity among veterans affairs patients receiving linezolid and vancomycin. Antimicrob Agents Chemother. 2013 Dec;57(12):5901–5911.
   PubMed Web of Science ®Google Scholar
• Hendershot PE, Antal EJ, Welshman IR, et al. Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. J Clin Pharmacol. 2001 May;41(5):563–572.
   PubMed Web of Science ®Google Scholar
• Nukui Y, Hatakeyama S, Okamoto K, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013 Sep;68(9):2128–2133.
   PubMed Web of Science ®Google Scholar
• Moran GJ, Fang E, Corey GR, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014 Aug;14(8):696–705.
   PubMed Web of Science ®Google Scholar
• Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. Jama. 2013 Feb 13;309(6):559–569.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Fang E, Minassian SL, et al. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials. Antimicrob Agents Chemother. 2014 Dec;58(12):7198–7204.
   PubMed Web of Science ®Google Scholar
• Fang E, Munoz KA, Prokocimer P. Characterization of neurologic and ophthalmologic safety of oral administration of tedizolid for up to 21 days in healthy volunteers. Am J Ther. 2017 Mar;24(2):e227–e233. Apr.
   PubMed Web of Science ®Google Scholar
• Flanagan S, Bartizal K, Minassian SL, et al. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother. 2013 Jul;57(7):3060–3066.
   PubMed Web of Science ®Google Scholar
• Flanagan S, Minassian SL, Prokocimer P. Pharmacokinetics of tedizolid and pseudoephedrine administered alone or in combination in healthy volunteers. J Clin Med. 2018 Jun 14;7(6).
   PubMed Web of Science ®Google Scholar
• O’Riordan W, Green S, Mehra P, et al. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary. Clin Infect Dis. 2014 Jan;58(Suppl 1):S43–50.
   PubMed Web of Science ®Google Scholar
• Company PU. Zyvox (linezolid) [prescribing information]. New York; 2014.
   Google Scholar
• US CP. Sivextro (tedizolid phosphate) [prescribing information]. Lexington, MA; 2014.
   Google Scholar
• Lee SY, Fan HW, Kuti JL, et al. Update on daptomycin: the first approved lipopeptide antibiotic. Expert Opin Pharmacother. 2006 Jul;7(10):1381–1397.
   PubMedGoogle Scholar
• Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004 Jun 15;38(12):1673–1681.
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Ambrose PG, Hammel JP, et al. Evaluation of daptomycin exposure and efficacy and safety endpoints to support risk-versus-benefit considerations. Antimicrob Agents Chemother. 2015 Dec 28;60(3):1600–1607.
   PubMed Web of Science ®Google Scholar
• Dare RK, Tewell C, Harris B, et al. Effect of statin coadministration on the risk of daptomycin-associated myopathy. Clin Infect Dis. 2018 Oct 15;67(9):1356–1363.
   PubMed Web of Science ®Google Scholar
• Papadopoulos S, Ball AM, Liewer SE, et al. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis. 2006 Jun 15;42(12):e108–10.
   PubMed Web of Science ®Google Scholar
• Seaton RA, Gonzalez-Ruiz A, Cleveland KO, et al. Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. Ann Clin Microbiol Antimicrob. 2016 Mar;15(15):18.
   PubMed Web of Science ®Google Scholar
• Administration UFaD. FDA drug safety communication: eosinophilic pneumonia associated with the use of cubicin (daptomycin). cited 03 Feb 2019: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm220273.htm.
   Google Scholar
• West K MK, Forrest GN. Daptomycin pulmonary eosinophilia: review of cases and new hyperacute syndromic presentation. Open Forum Infect Dis. 2018;5(Suppl 1):S717.
   Google Scholar
• Farber J, Illiger S, Berger F, et al. Management of a cluster of clostridium difficile infections among patients with osteoarticular infections. Antimicrob Resist Infect Control. 2017;6:22.
   PubMed Web of Science ®Google Scholar
• Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003 Sep;47(9):2775–2780.
   PubMed Web of Science ®Google Scholar
• Kielstein JT, Eugbers C, Bode-Boeger SM, et al. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis–a pharmacokinetic study. Nephrol Dial Transplant. 2010 May;25(5):1537–1541.
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014 Jul 15;59(2):e10–52.
   PubMed Web of Science ®Google Scholar
• Diaz R, Afreixo V, Ramalheira E, et al. Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections-a systematic review and meta-analysis. Clin Microbiol Infect. 2018 Feb;24(2):97–104.
   PubMed Web of Science ®Google Scholar
• Yeh YC, Yeh KM, Lin TY, et al. Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia. J Microbiol Immunol Infect. 2012 Jun;45(3):214–220.
   PubMedGoogle Scholar
• Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Am J Health Syst Pharm. 2009 Jan 1;66(1):82–98.
   PubMedGoogle Scholar
• Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis. 2004 Jun 15;38(12):1700–1705.
   PubMed Web of Science ®Google Scholar
• Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. Clin Pharmacol Ther. 2017 Sep;102(3):459–469.
   PubMed Web of Science ®Google Scholar
• Sivagnanam S, Deleu D. Red man syndrome. Crit Care. 2003 Apr;7(2):119–120.
   PubMed Web of Science ®Google Scholar
• Darko W, Medicis JJ, Smith A, et al. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy. 2003 May;23(5):643–650.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang XY, Zeckel M, et al. Risk of hepatic events in patients treated with vancomycin in clinical studies: a systematic review and meta-analysis. Drug Saf. 2011 Jan 1;34(1):73–82.
   PubMed Web of Science ®Google Scholar
• Black E, Lau TT, Ensom MH. Vancomycin-induced neutropenia: is it dose- or duration-related? Ann Pharmacother. 2011 May;45(5):629–638.
   PubMed Web of Science ®Google Scholar
• Economics M Vancocin® HCl. Sterile vancomycin hydrochloride; intravenous. In Physicians’ desk reference, 55th ed Medical Economics; Montvale, NJ; 2001.
   Google Scholar
• Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 2000 Sep;39(3):167–183.
   PubMed Web of Science ®Google Scholar
• Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother. 2009 Oct;53(10):4069–4079.
   PubMed Web of Science ®Google Scholar
• Wilson AP. Comparative safety of teicoplanin and vancomycin. Int J Antimicrob Agents. 1998 May;10(2):143–152.
   PubMed Web of Science ®Google Scholar
• Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother. 1996 Feb;37(2):209–222.
   PubMed Web of Science ®Google Scholar
• Cavalcanti AB, Goncalves AR, Almeida CS, et al. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev. 2010 Jun;16(6):CD007022.
   Google Scholar
• Bassetti M, Peghin M, Carnelutti A, et al. The role of dalbavancin in skin and soft tissue infections. Curr Opin Infect Dis. 2018 Apr;31(2):141–147.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014 Jun 5;370(23):2169–2179.
   PubMed Web of Science ®Google Scholar
• Bouza E, Valerio M, Soriano A, et al. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018 Apr;51(4):571–577.
   PubMed Web of Science ®Google Scholar
• Marbury T, Dowell JA, Seltzer E, et al. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol. 2009 Apr;49(4):465–476.
   PubMed Web of Science ®Google Scholar
• Fetterly GJ, Ong CM, Bhavnani SM, et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200 milligram dose for 3 days or a single 800 milligram dose. Antimicrob Agents Chemother. 2005 Jan;49(1):148–152.
   PubMed Web of Science ®Google Scholar
• Corey GR, Good S, Jiang H, et al. Single-dose oritavancin versus 7–10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015 Jan 15;60(2):254–262.
   PubMed Web of Science ®Google Scholar
• Corey GR, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014 Jun 5;370(23):2180–2190.
   PubMed Web of Science ®Google Scholar
• Redell M, Moeck G, Lucasti C, et al. A real-world patient registry for oritavancin demonstrates efficacy and safety consistent with the phase 3 SOLO program. Open Forum Infect Dis. 2018 Jun;5(6):ofy051.
   PubMed Web of Science ®Google Scholar
• Polyzos KA, Mavros MN, Vardakas KZ, et al. Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. PLoS One. 2012;7(8):e41870.
   PubMed Web of Science ®Google Scholar
• Worboys PD, Wong SL, Barriere SL. Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment. Eur J Clin Pharmacol. 2015 Jun;71(6):707–714.
   PubMed Web of Science ®Google Scholar
• Feher C, Soriano A, Mensa J. A review of experimental and off-label therapies for clostridium difficile infection. Infect Dis Ther. 2017 Mar;6(1):1–35.
   PubMed Web of Science ®Google Scholar
• Sader HS, Biedenbach DJ, Paukner S, et al. Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against gram-positive organisms commonly associated with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2012 Mar;56(3):1619–1623.
   PubMed Web of Science ®Google Scholar
• Prince WT, Ivezic-Schoenfeld Z, Lell C, et al. Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2013 May;57(5):2087–2094.
   PubMed Web of Science ®Google Scholar
• File TM Jr., Goldberg L, Das A, et al. Efficacy and safety of iv-to-oral lefamulin, a pleuromutilin antibiotic, for treatment of community-acquired bacterial pneumonia: the phase 3 LEAP 1 trial. Clin Infect Dis. 2019 Feb 4.
   Web of Science ®Google Scholar
• Bassetti M, Baguneid M, Bouza E, et al. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect. 2014 Apr;20(Suppl 4):3–18.
   PubMed Web of Science ®Google Scholar
• Pulido-Cejudo A, Guzman-Gutierrez M, Jalife-Montano A, et al. Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure. Ther Adv Infect Dis. 2017 Sep;4(5):143–161.
   PubMed Web of Science ®Google Scholar
• Pai MP. Anti-infective dosing for obese adult patients: a focus on newer drugs to treat methicillin-resistant Staphylococcus aureus acute bacterial skin and skin structure infections. Clin Ther. 2016 Sep;38(9):2032–2044.
   PubMed Web of Science ®Google Scholar
• Meng L, Mui E, Holubar MK, et al. Comprehensive guidance for antibiotic dosing in obese adults. Pharmacotherapy. 2017 Nov;37(11):1415–1431.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. NCT02753855 April 28, 2016.
   Google Scholar
• Lipsky BA, Giordano P, Choudhri S, et al. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother. 2007 Aug;60(2):370–376.
   PubMed Web of Science ®Google Scholar
• Majcher-Peszynska J, Sass M, Schipper S, et al. Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. Eur J Clin Pharmacol. 2011 Feb;67(2):135–142.
   PubMed Web of Science ®Google Scholar
• Nowak M RU, Gonzalez PL. Efficacy and safety of dalbavancin for the treatment of acute bacterial skin and skin structure infection (ABSSSI) in patients with diabetes mellitus. Open Forum Infect Dis. 2017;4(Suppl 1):S95.
   Web of Science ®Google Scholar
• Bassetti M, Eckmann C, Peghin M, et al. When to switch to an oral treatment and/or to discharge a patient with skin and soft tissue infections. Curr Opin Infect Dis. 2018 Apr;31(2):163–169.
   PubMed Web of Science ®Google Scholar